Devrim Cabuk

582 citations
6 papers · 420 · 1 hit paper · h-index 4

Impact in

  • Oncology top 10%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Cancer survivorship and care
    • Cancer Risks and Factors
    • Breast Cancer Treatment Studies

Papers in

    • Cancer survivorship and care 1
    • Cancer Risks and Factors 1
    • Lung Cancer Research Studies 1
    • HER2/EGFR in Cancer Research 1
    • Breast Cancer Treatment Studies 2

Devrim Cabuk

6 papers receiving 405 citations

Devrim Cabuk's Hit Papers

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer 2022 · 345 citations
3450+1+2Years since publication100200300

Peers

Devrim Cabuk
Comparison fields: 5 of 31
  • Oncology 320
  • Cancer Research 26
  • Pulmonary and Respiratory Medicine 51
  • Economics and Econometrics 24
  • Molecular Biology 21
Replace Dongji Chen with:
Dongji Chen China
Ekaterine Arkania United States
Denys Pominchuk Ukraine
Sreekanth Reddy United States
Reija Koukakis United Kingdom
Y.J. Chua Australia
Antonio Santaniello Italy
Yasir M. Nagarwala United States
Timur Andabekov Russia
K. Yamazaki Japan
Devrim Cabuk relative to Dongji Chen China Dongji Chen's profile →
Citations per field
00.5×2×2.8×
Dongji Chen · 1×
Citations per year

Countries citing papers authored by Devrim Cabuk

Since Specialization
Citations

This map shows the geographic impact of Devrim Cabuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devrim Cabuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devrim Cabuk more than expected).

Fields of papers citing papers by Devrim Cabuk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devrim Cabuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devrim Cabuk. The network helps show where Devrim Cabuk may publish in the future.

Co-authors

The 12 scholars most cited alongside Devrim Cabuk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Devrim Cabuk Line = papers co-authored together Devrim Cabuk links everyone, so they are left out of the graph.

All Works

6 of 6 papers shown
#Work
1
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Hit paper breakdown →
2022345
2 200734
3 201021
4 201018
5 20251
6 20251

About Devrim Cabuk

Devrim Cabuk is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Nuclear Energy and Engineering, having authored 6 papers that have together received 420 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (2 papers), Advanced Breast Cancer Therapies (1 paper), Cancer survivorship and care (1 paper), Angiogenesis and VEGF in Cancer (1 paper), Cancer Risks and Factors (1 paper), Lung Cancer Research Studies (1 paper), HER2/EGFR in Cancer Research (1 paper) and Gastric Cancer Management and Outcomes (1 paper). The work is most often cited by research in Oncology (320 citations), Cancer Research (26 citations), Pulmonary and Respiratory Medicine (51 citations), Economics and Econometrics (24 citations) and Molecular Biology (21 citations). Devrim Cabuk has collaborated with scholars based in Türkiye. Frequent co-authors include Gül Başaran, Faysal Dane, Perran Fulden Yumuk, Nazım Serdar Turhal, Meltem Ekenel, Çiğdem Çelikel, Mahmut Bahadir Gulluoglu, Taner Korkmaz, Hale Başak Çağlar and S. Seber. Their work appears in journals such as Medical Oncology, Oncology, Anti-Cancer Drugs, JAMA and Clinical Breast Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact